Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/35401
Title: | Photobiomodulation therapy for the prevention of acute radiation dermatitis in breast cancer patients undergoing hypofractioned whole‐breast irradiation (LABRA trial) | Authors: | ROBIJNS, Jolien LODEWIJCKX, Joy Van Bever, Leen Puts, Sofie Timmermans, An Noe, Leen Vanmechelen, Sofie Govers, Mieke Van de Werf, Evelyn MAES, Annelies BULENS, Paul MEBIS, Jeroen Claes, Stefan Pannekoeke, Luc |
Issue Date: | 2022 | Publisher: | WILEY | Source: | LASERS IN SURGERY AND MEDICINE; 54 (3) , p. 374-383 | Abstract: | Objectives To evaluate the efficacy of photobiomodulation therapy in breast cancer patients post-lumpectomy undergoing hypofractionated whole-breast irradiation (HF-WBI) for the prevention and management of acute radiodermatitis (ARD). Materials and Methods A randomized, multicentric clinical trial (LABRA trial, NCT03924011) was set up at the Limburg Oncology Center, including the Jessa Hospital (Hasselt, BE) and Ziekenhuis Oost-Limburg (Genk, BE). A total of 71 breast cancer patients planned to undergo HF-WBI were randomized to one of the two study arms: the control group (n = 32) or the PBM group (n = 39). The PBM group received the standard institutional skincare combined with PBM (2x/week) during the complete radiotherapy (RT) course. Patients in the control group received the standard skincare combined with placebo treatment (2x/week). Patients' skin reactions were evaluated weekly during the RT treatment by using the modified version of the Radiation Therapy Oncology Group (RTOG) criteria. Results At week 3 of RT, one patient presented a grade 2 and one patient a grade 3 skin reaction in the control group, while in the PBM group, all patients still presented grade 1 ARD. At the final RT session 28% of the patients presenting grade 2-3 ARD, while in the PBM group 10% presented grade 2 and no grade 3 ARD. PBM reduced the incidence of severe ARD by 18%. However, the difference was not significant (p = 0.053). Conclusion Based on the LABRA trial results, PBM seems not able to reduce the incidence of severe ARD in breast cancer patients undergoing HF-WBI. Research in a larger patient population is recommended. | Notes: | Robijns, J (corresponding author), Hasselt Univ, Fac Med & Life Sci, Martelarenlaan 42, B-3500 Hasselt, Belgium. Jolien.robijns@uhasselt.be |
Keywords: | acute radiodermatitis;breast cancer;dermatology;photobiomodulation therapy;radiotherapy;skin | Document URI: | http://hdl.handle.net/1942/35401 | ISSN: | 0196-8092 | e-ISSN: | 1096-9101 | DOI: | 10.1002/lsm.23475 | ISI #: | WOS:000693508200001 | Rights: | 2021 Wiley Periodicals LLC | Category: | A1 | Type: | Journal Contribution | Validations: | ecoom 2022 |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Lasers Surg Med - 2021 - Robijns - Photobiomodulation therapy for the prevention of acute radiation dermatitis in breast.pdf Restricted Access | Published version | 367.93 kB | Adobe PDF | View/Open Request a copy |
WEB OF SCIENCETM
Citations
7
checked on Oct 10, 2024
Page view(s)
74
checked on Sep 7, 2022
Download(s)
8
checked on Sep 7, 2022
Google ScholarTM
Check
Altmetric
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.